3 results
Primary1. To assess the hematologic response and return to chronic phase rate in patients with accelerate phase or blasts crisis whose diseae is resistant following treatment with at lest two BCR-ABL tyrosine kinase inhibitors when treated with…
The primary objective of this study is to evaluate the efficacy of SCH 503034800 mg TID PO in combination with PegIntron 1.5 *g/kg QW SC plus ribavirin (800 - 1400 mg/day) in previously untreated adult chronic hepatitis C (CHC) subjects infected…
PrimaryTo determine the hematological response (complete response(CR) / partial response (PR)) rate as per Bladé criteria to treatment with oral LBH589 of patients with MM who have received at least two prior lines of therapy and whose disease is…